Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations.

This is the first report describing TFS data among patients with NSCLC with EGFR mutations who received EGFR-TKI and PT as the initial two regimens. TFS was acceptable as a surrogate endpoint for OS. Further validation in clinical trials is needed.